Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma

BACKGROUND: Gastric cancer (GC) is one of the most common malignant cancers worldwide. The development of potential antitumor agents is being investigated and stimulates more clinical trials. Overall survival (OS) is consistently considered the primary endpoint for clinical trials on treatment effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hua, Wang, Yakun, Qi, Changsong, Xie, Tong, Peng, Zhi, Li, Jian, Shen, Lin, Zhang, Xiaotian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022778/
https://www.ncbi.nlm.nih.gov/pubmed/35463354
http://dx.doi.org/10.3389/fonc.2022.835389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9022778/
https://www.ncbi.nlm.nih.gov/pubmed/35463354
http://dx.doi.org/10.3389/fonc.2022.835389

Ejemplares similares